SSY Group Limited (HK:2005)
:2005
Top Page
SSY Group
(2005)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$3.00
▲(2.39% Upside)
Action:ReiteratedDate:10/23/25
SSY Group's overall stock score of 59 is primarily driven by mixed financial performance (score: 55, weight: 50%), with stable profitability margins offset by declining revenue and significant cash flow concerns (negative Free Cash Flow of -49.4M). Valuation (score: 70, weight: 20%) provides a positive lift with a reasonable P/E ratio (12.95) and attractive dividend yield (4.77%). Technical analysis (score: 60, weight: 30%) indicates a neutral to slightly positive trend but with mixed momentum signals. Investors should weigh cash flow risks against valuation strengths.
Positive Factors
Strong Profitability
A consistent high gross profit margin indicates effective cost management and pricing power, contributing to sustainable profitability.
Negative Factors
Revenue Decline
A decline in revenue growth may signal challenges in market expansion or competitive pressures, potentially impacting future earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
A consistent high gross profit margin indicates effective cost management and pricing power, contributing to sustainable profitability.
Read all positive factors
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.38B
Dividend Yield4.93%
Average Volume (3M)5.65M
Price to Earnings (P/E)17.6
Beta (1Y)0.62
Revenue Growth-29.18%
EPS Growth-51.49%
CountryHK
Employees6,146
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.06
Shares Outstanding2,951,113,300
10 Day Avg. Volume4,536,404
30 Day Avg. Volume5,652,093
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)1.46
Price to Sales (P/S)1.83
P/FCF Ratio-214.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.20Price Target Upside43.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.21
Revenue Forecast (FY)HK$4.88B
SSY Group Business Overview & Revenue Model
Company Description
SSY Group (2005) is a diversified company specializing in the manufacturing and distribution of pharmaceuticals and healthcare products. With a strong emphasis on quality and innovation, SSY Group operates in various sectors including generic phar...
How the Company Makes Money
SSY Group generates revenue primarily through the sale of its pharmaceutical products, which include both branded and generic medications. A significant portion of its income comes from the production and distribution of active pharmaceutical ingr...
SSY Group Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.58B | 5.77B | 6.46B | 6.43B | 5.36B | 4.26B |
| Gross Profit | 1.96B | 2.91B | 3.62B | 3.44B | 3.04B | 2.58B |
| EBITDA | 1.25B | 1.74B | 2.11B | 1.86B | 1.40B | 1.09B |
| Net Income | 658.92M | 1.06B | 1.32B | 1.12B | 785.53M | 611.97M |
Balance Sheet | ||||||
| Total Assets | 12.79B | 12.60B | 11.97B | 10.97B | 10.71B | 9.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.52B | 1.29B | 1.62B | 1.71B | 1.70B | 1.51B |
| Total Debt | 4.02B | 3.64B | 3.37B | 3.21B | 3.11B | 2.44B |
| Total Liabilities | 5.19B | 5.07B | 4.70B | 4.42B | 4.22B | 3.34B |
| Stockholders Equity | 7.27B | 7.22B | 6.93B | 6.21B | 6.22B | 5.65B |
Cash Flow | ||||||
| Free Cash Flow | 94.40M | -49.39M | 221.88M | 368.70M | 359.58M | 236.61M |
| Operating Cash Flow | 381.69M | 491.03M | 925.75M | 786.82M | 747.91M | 527.64M |
| Investing Cash Flow | -354.67M | -521.76M | -640.19M | -402.72M | -681.23M | -287.58M |
| Financing Cash Flow | -234.64M | -295.42M | -304.57M | -190.51M | 136.13M | 366.35M |
SSY Group Technical Analysis
Neutral
2.93
Price Trends
2.72
Negative
2.87
Negative
2.91
Negative
Market Momentum
-0.06
Negative
46.38
Neutral
63.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2005, the sentiment is Neutral. The current price of 2.93 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.72, and above the 200-day MA of 2.91, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 46.38 is Neutral, neither overbought nor oversold. The STOCH value of 63.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2005.
SSY Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$7.37B | 6.31 | 10.84% | 5.80% | -20.64% | -25.39% | |
72 Outperform | HK$14.03B | 11.34 | 24.04% | 3.93% | 19.05% | 13.68% | |
66 Neutral | HK$1.74B | 7.90 | 5.33% | 5.16% | 2.89% | -68.83% | |
59 Neutral | HK$7.38B | 17.64 | 9.09% | 4.93% | -29.18% | -51.49% | |
58 Neutral | HK$9.88B | 14.45 | 7.49% | 4.47% | 1.65% | -16.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$13.16B | 22.81 | -1.84% | 0.87% | 19.21% | -115.91% |
* Healthcare Sector Average
HK:2005
SSY Group
2.50
-0.33
-11.57%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.41
0.85
153.60%
HK:1681
Consun Pharmaceutical Group Ltd.
17.07
9.04
112.68%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.16
0.14
13.73%
HK:2877
China Shineway Pharmaceutical Group Limited
9.76
2.90
42.27%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.40
1.43
28.75%
SSY Group Corporate Events
SSY Group Wins China Approval for New Hypertension Combination Drug
Jan 5, 2026
SSY Group Limited has secured approval from China’s National Medical Products Administration for the production and registration of its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical drug that has passed consis...
SSY Group Wins NMPA Approval for Sodium Glycerophosphate Injection
Dec 29, 2025
SSY Group Limited has received approval from China’s National Medical Products Administration to produce and register its Sodium Glycerophosphate Injection (10ml:2.16g), classified as a type 4 chemical drug and deemed to have passed consiste...
SSY Group Renews Key Connected Transactions with Sichuan Kelun for 2026
Dec 23, 2025
SSY Group has renewed its core commercial arrangements with substantial shareholder Sichuan Kelun for 2026, signing a Master Sale and Purchase Agreement and a Master Products Manufacturing Service Agreement to continue the sale and purchase of mat...
SSY Group Gains Approval for New Drug Developments
Dec 11, 2025
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new drugs: Acetylcysteine Injection and Compound Sodium Acetate Ringer’s Injection. These approvals...
SSY Group Expands Pharmaceutical Portfolio with New Approvals
Dec 9, 2025
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules. These approvals expand the company’s ...
SSY Group’s Finerenone Gains Approval in China, Boosting Market Position
Dec 5, 2025
SSY Group Limited has announced that its product, Finerenone, has received approval from the National Medical Products Administration of China for registration as a bulk drug for market preparations. This approval marks the second such endorsement...
SSY Group Secures Approval for New Pharmaceutical Products
Dec 4, 2025
SSY Group Limited has announced that its products, Bilastine and Sodium Picosulfate, have received approval from the National Medical Products Administration of China for market preparation as bulk drugs. This development is significant for the co...
SSY Group Secures Approval for New Drug Production in China
Nov 28, 2025
SSY Group Limited has announced that it received approval from the National Medical Products Administration of China for the production and registration of Tolterodine Tartrate Sustained-release Capsules, a treatment for overactive bladder. This a...
SSY Group’s Vitamin A Palmitate Gains Approval in China
Nov 27, 2025
SSY Group Limited announced that its Vitamin A Palmitate has received approval from the National Medical Products Administration of China, allowing it to be marketed as a bulk drug for vitamin supplement injections. This development marks a signif...
SSY Group Secures Key Drug Approvals in China
Nov 24, 2025
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of several drugs, including Aminophylline Tablets, Procaterol Hydrochloride Inhalation Solution, and Ademetionin...
SSY Group Gains Approval for Indobufen Tablets
Nov 14, 2025
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Indobufen Tablets, a type 3 chemical drug. This development marks a significant step in the company’s p...
SSY Group’s Lincomycin Injection Gains Approval in China
Nov 3, 2025
SSY Group Limited has announced that its Lincomycin Hydrochloride Injection has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development is significan...
SSY Group Gains Approval for Three New Bulk Drugs in China
Nov 3, 2025
SSY Group Limited has announced the approval of three bulk drugs—Fenofibrate, Choline Fenofibrate, and Levornidazole Disodium Phosphate—by China’s National Medical Products Administration. These approvals enhance the company̵...
SSY Group’s Vitamin B6 Injection Gains Regulatory Approval in China
Nov 3, 2025
SSY Group Limited has announced that its Vitamin B6 Injection has received approval from the National Medical Products Administration of China for the Consistency Evaluation of the Quality and Efficacy of Generic Drugs. This development signifies ...
SSY Group Reports Significant Decline in Nine-Month Operating Results
Oct 28, 2025
SSY Group Limited reported a significant decline in its unaudited operating results for the nine months ended September 30, 2025, with turnover decreasing by 31.6% and gross profit dropping by 46.1% compared to the previous year. The company attri...
SSY Group’s Products Selected in National Medicines Procurement
Oct 28, 2025
SSY Group Limited announced that 12 of its products with 14 specifications were selected in the eleventh batch of the National Centralised Medicines Procurement in China. This selection is a significant development for the company, potentially enh...
SSY Group Gains Approval for New Hypertension Drug
Oct 17, 2025
SSY Group Limited has announced the approval of Levamlodipine Besilate Tablets by the National Medical Products Administration of China. This development signifies a strategic advancement in their product offerings, potentially enhancing their mar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.